A Phase 2, Multicenter, Single-arm, Open Label Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
Price : $35 *
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 17 Aug 2017 Status changed from active, no longer recruiting to completed.
- 04 May 2017 Planned End Date changed from 1 Mar 2017 to 3 Jul 2017.
- 04 May 2017 Planned primary completion date changed from 1 Mar 2017 to 3 Jul 2017.